This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $483,360 to the University of California, San Diego (UCSD) to conduct research aimed at identifying new precision therapies for oral cancer. The key focus is to exploit vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry to disrupt immune evasive mechanisms and enhance the activity of anti-PD-1 immunotherapies for head and neck squamous cell carcinoma (HNSCC). The award has a period of performance from July 1, 2025 to June 30, 2030. The research will be primarily conducted at UCSD.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $483.4k | 6/26/25 |